Decitabine

Post-transplant maintenance for patients with AML 6:22
Post-transplant maintenance for patients with AML
Ali Bazarbachi • 12 Mar 2021
Prolonging remission in AML 3:26
Prolonging remission in AML
Farhad Ravandi • 11 Mar 2021
TP53-mutant AML linked to poorer outcomes with decitabine plus venetoclax 1:48
TP53-mutant AML linked to poorer outcomes with decitabine plus venetoclax
Kunhwa Kim • 17 Dec 2020
Cytoreductive therapy is safe and feasible for newly-diagnosed AML 1:21
Cytoreductive therapy is safe and feasible for newly-diagnosed AML
Kunhwa Kim • 17 Dec 2020
Higher-risk MDS in 2021: pevonedistat, sabatolimab & APR-246 5:05
Higher-risk MDS in 2021: pevonedistat, sabatolimab & APR-246
Valeria Santini • 25 Jan 2021
MDS: managing HMA failure 3:32
MDS: managing HMA failure
Valeria Santini • 25 Jan 2021
The 2021 MDS armamentarium 4:05
The 2021 MDS armamentarium
Felicitas Thol • 22 Jan 2021
Phase Ib/II trial of quizartinib, decitabine and venetoclax in FLT3-ITD-mutated AML 4:15
Phase Ib/II trial of quizartinib, decitabine and venetoclax in FLT3-ITD-mutated AML
Musa Yilmaz • 7 Dec 2020
MRD negativity predicts improved survival in AML 2:53
MRD negativity predicts improved survival in AML
Farhad Ravandi • 10 Dec 2020
Effect of BMT status on decitabine plus ipilimumab in R/R MDS/AML 8:35
Effect of BMT status on decitabine plus ipilimumab in R/R MDS/AML
Jacqueline Garcia • 4 Dec 2020
Venetoclax plus HMAs in IDH-mutant AML 5:35
Venetoclax plus HMAs in IDH-mutant AML
Danielle Hammond • 7 Dec 2020
Outcomes of TP53-mutant AML with venetoclax and decitabine 2:36
Outcomes of TP53-mutant AML with venetoclax and decitabine
Marina Konopleva • 30 Nov 2020
Decitabine vs hydroxyurea for advanced proliferative CMML 3:55
Decitabine vs hydroxyurea for advanced proliferative CMML
Raphael Itzykson • 2 Dec 2020
Phase I trial of decitabine plus ipilimumab in R/R MDS & AML 1:37
Phase I trial of decitabine plus ipilimumab in R/R MDS & AML
Daniel DeAngelo • 3 Dec 2020
Decitabine plus venetoclax is comparable to intensive chemotherapy in R/R AML 2:34
Decitabine plus venetoclax is comparable to intensive chemotherapy in R/R AML
Marina Konopleva • 30 Nov 2020
Onvansertib plus decitabine for patients with R/R AML 1:32
Onvansertib plus decitabine for patients with R/R AML
Eunice Wang • 24 Nov 2020
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals